Dermira has suffered a surprising and catastrophic failure of its experimental acne drug.
Across two separate but identically designed Phase 3 clinical trials, Dermira’s drug, a topical gel called DRM01, did not achieve any of its endpoints when compared to an inactive control gel, the company said Monday.
Dermira is still sifting through the rubble of its failed studies, but it does not expect to continue developing DRM01 any further.
About the Author Reprints
